Consensus recommendations for risk stratification in multiple myeloma: Report of the International Myeloma Workshop Consensus Panel 2

Nikhil C. Munshi, Kenneth C. Anderson, Peter Leif Bergsagel, John Shaughnessy, Antonio Palumbo, Brian Durie, Rafael Fonseca, Alexander Keith Stewart, Jean Luc Harousseau, Meletios Dimopoulos, Sundar Jagannath, Roman Hajek, Orhan Sezer, Robert Kyle, Pieter Sonneveld, Michele Cavo, S Vincent Rajkumar, Jesus San Miguel, John Crowley, Hervé Avet-Loiseau

Research output: Contribution to journalArticle

240 Citations (Scopus)

Abstract

A panel of members of the 2009 International Myeloma Workshop developed guidelines for risk stratification in multiple myeloma. The purpose of risk stratification is not to decide time of therapy but to prognosticate. There is general consensus that risk stratification is applicable to newly diagnosed patients; however, some genetic abnormalities characteristic of poor outcome at diagnosis may suggest poor outcome if only detected at the time of relapse. Thus, in good-risk patients, it is necessary to evaluate for high-risk features at relapse. Although detection of any cytogenetic abnormality is considered to suggest higher-risk disease, the specific abnormalities considered as poor risk are cytogenetically detected chromosomal 13 or 13q deletion, t(4;14) and del17p, and detection by fluorescence in situ hybridization of t(4;14), t(14;16), and del17p. Detection of 13q deletion by fluorescence in situ hybridization only, in absence of other abnormalities, is not considered a high-risk feature. High serumβ2-microglobulin level and International Staging System stages II and III, incorporating high β 2-microglobulin and low albumin, are considered to predict higher risk disease. There was a consensus that the high-risk features will change in the future, with introduction of other new agents or possibly new combinations.

Original languageEnglish (US)
Pages (from-to)4696-4700
Number of pages5
JournalBlood
Volume117
Issue number18
DOIs
StatePublished - May 5 2011

Fingerprint

Consensus Development Conferences
Multiple Myeloma
Fluorescence In Situ Hybridization
Fluorescence
Recurrence
Chromosome Aberrations
Albumins

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Consensus recommendations for risk stratification in multiple myeloma : Report of the International Myeloma Workshop Consensus Panel 2. / Munshi, Nikhil C.; Anderson, Kenneth C.; Bergsagel, Peter Leif; Shaughnessy, John; Palumbo, Antonio; Durie, Brian; Fonseca, Rafael; Stewart, Alexander Keith; Harousseau, Jean Luc; Dimopoulos, Meletios; Jagannath, Sundar; Hajek, Roman; Sezer, Orhan; Kyle, Robert; Sonneveld, Pieter; Cavo, Michele; Rajkumar, S Vincent; San Miguel, Jesus; Crowley, John; Avet-Loiseau, Hervé.

In: Blood, Vol. 117, No. 18, 05.05.2011, p. 4696-4700.

Research output: Contribution to journalArticle

Munshi, NC, Anderson, KC, Bergsagel, PL, Shaughnessy, J, Palumbo, A, Durie, B, Fonseca, R, Stewart, AK, Harousseau, JL, Dimopoulos, M, Jagannath, S, Hajek, R, Sezer, O, Kyle, R, Sonneveld, P, Cavo, M, Rajkumar, SV, San Miguel, J, Crowley, J & Avet-Loiseau, H 2011, 'Consensus recommendations for risk stratification in multiple myeloma: Report of the International Myeloma Workshop Consensus Panel 2', Blood, vol. 117, no. 18, pp. 4696-4700. https://doi.org/10.1182/blood-2010-10-300970
Munshi, Nikhil C. ; Anderson, Kenneth C. ; Bergsagel, Peter Leif ; Shaughnessy, John ; Palumbo, Antonio ; Durie, Brian ; Fonseca, Rafael ; Stewart, Alexander Keith ; Harousseau, Jean Luc ; Dimopoulos, Meletios ; Jagannath, Sundar ; Hajek, Roman ; Sezer, Orhan ; Kyle, Robert ; Sonneveld, Pieter ; Cavo, Michele ; Rajkumar, S Vincent ; San Miguel, Jesus ; Crowley, John ; Avet-Loiseau, Hervé. / Consensus recommendations for risk stratification in multiple myeloma : Report of the International Myeloma Workshop Consensus Panel 2. In: Blood. 2011 ; Vol. 117, No. 18. pp. 4696-4700.
@article{233521fa996c447cb0d6b88230ec5c02,
title = "Consensus recommendations for risk stratification in multiple myeloma: Report of the International Myeloma Workshop Consensus Panel 2",
abstract = "A panel of members of the 2009 International Myeloma Workshop developed guidelines for risk stratification in multiple myeloma. The purpose of risk stratification is not to decide time of therapy but to prognosticate. There is general consensus that risk stratification is applicable to newly diagnosed patients; however, some genetic abnormalities characteristic of poor outcome at diagnosis may suggest poor outcome if only detected at the time of relapse. Thus, in good-risk patients, it is necessary to evaluate for high-risk features at relapse. Although detection of any cytogenetic abnormality is considered to suggest higher-risk disease, the specific abnormalities considered as poor risk are cytogenetically detected chromosomal 13 or 13q deletion, t(4;14) and del17p, and detection by fluorescence in situ hybridization of t(4;14), t(14;16), and del17p. Detection of 13q deletion by fluorescence in situ hybridization only, in absence of other abnormalities, is not considered a high-risk feature. High serumβ2-microglobulin level and International Staging System stages II and III, incorporating high β 2-microglobulin and low albumin, are considered to predict higher risk disease. There was a consensus that the high-risk features will change in the future, with introduction of other new agents or possibly new combinations.",
author = "Munshi, {Nikhil C.} and Anderson, {Kenneth C.} and Bergsagel, {Peter Leif} and John Shaughnessy and Antonio Palumbo and Brian Durie and Rafael Fonseca and Stewart, {Alexander Keith} and Harousseau, {Jean Luc} and Meletios Dimopoulos and Sundar Jagannath and Roman Hajek and Orhan Sezer and Robert Kyle and Pieter Sonneveld and Michele Cavo and Rajkumar, {S Vincent} and {San Miguel}, Jesus and John Crowley and Herv{\'e} Avet-Loiseau",
year = "2011",
month = "5",
day = "5",
doi = "10.1182/blood-2010-10-300970",
language = "English (US)",
volume = "117",
pages = "4696--4700",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "18",

}

TY - JOUR

T1 - Consensus recommendations for risk stratification in multiple myeloma

T2 - Report of the International Myeloma Workshop Consensus Panel 2

AU - Munshi, Nikhil C.

AU - Anderson, Kenneth C.

AU - Bergsagel, Peter Leif

AU - Shaughnessy, John

AU - Palumbo, Antonio

AU - Durie, Brian

AU - Fonseca, Rafael

AU - Stewart, Alexander Keith

AU - Harousseau, Jean Luc

AU - Dimopoulos, Meletios

AU - Jagannath, Sundar

AU - Hajek, Roman

AU - Sezer, Orhan

AU - Kyle, Robert

AU - Sonneveld, Pieter

AU - Cavo, Michele

AU - Rajkumar, S Vincent

AU - San Miguel, Jesus

AU - Crowley, John

AU - Avet-Loiseau, Hervé

PY - 2011/5/5

Y1 - 2011/5/5

N2 - A panel of members of the 2009 International Myeloma Workshop developed guidelines for risk stratification in multiple myeloma. The purpose of risk stratification is not to decide time of therapy but to prognosticate. There is general consensus that risk stratification is applicable to newly diagnosed patients; however, some genetic abnormalities characteristic of poor outcome at diagnosis may suggest poor outcome if only detected at the time of relapse. Thus, in good-risk patients, it is necessary to evaluate for high-risk features at relapse. Although detection of any cytogenetic abnormality is considered to suggest higher-risk disease, the specific abnormalities considered as poor risk are cytogenetically detected chromosomal 13 or 13q deletion, t(4;14) and del17p, and detection by fluorescence in situ hybridization of t(4;14), t(14;16), and del17p. Detection of 13q deletion by fluorescence in situ hybridization only, in absence of other abnormalities, is not considered a high-risk feature. High serumβ2-microglobulin level and International Staging System stages II and III, incorporating high β 2-microglobulin and low albumin, are considered to predict higher risk disease. There was a consensus that the high-risk features will change in the future, with introduction of other new agents or possibly new combinations.

AB - A panel of members of the 2009 International Myeloma Workshop developed guidelines for risk stratification in multiple myeloma. The purpose of risk stratification is not to decide time of therapy but to prognosticate. There is general consensus that risk stratification is applicable to newly diagnosed patients; however, some genetic abnormalities characteristic of poor outcome at diagnosis may suggest poor outcome if only detected at the time of relapse. Thus, in good-risk patients, it is necessary to evaluate for high-risk features at relapse. Although detection of any cytogenetic abnormality is considered to suggest higher-risk disease, the specific abnormalities considered as poor risk are cytogenetically detected chromosomal 13 or 13q deletion, t(4;14) and del17p, and detection by fluorescence in situ hybridization of t(4;14), t(14;16), and del17p. Detection of 13q deletion by fluorescence in situ hybridization only, in absence of other abnormalities, is not considered a high-risk feature. High serumβ2-microglobulin level and International Staging System stages II and III, incorporating high β 2-microglobulin and low albumin, are considered to predict higher risk disease. There was a consensus that the high-risk features will change in the future, with introduction of other new agents or possibly new combinations.

UR - http://www.scopus.com/inward/record.url?scp=79956039754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956039754&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-10-300970

DO - 10.1182/blood-2010-10-300970

M3 - Article

C2 - 21292777

AN - SCOPUS:79956039754

VL - 117

SP - 4696

EP - 4700

JO - Blood

JF - Blood

SN - 0006-4971

IS - 18

ER -